The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group
Open accessAbstract
An open-label phase II study (ACNS0126) testing the efficacy of chemoradiotherapy with temozolomide (TMZ) followed by adjuvant TMZ was conducted by the Children's Oncology Group. During the period from July 6, 2004 through September 6, 2005, 63 children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) were enrolled in the study. All patients received TMZ at a dosage of 90 mg/m(2)/day for 42 days to a dose of 59.4 Gy. Four weeks following irradiation, TMZ was given at a dosage of 200 mg/m(2)/day for 5 days every 28 days, for a total of 10 cycles. The primary objective of the statistical analysis was to determine whether the current treatment produced a 1-year event-free survival (EFS) rate higher than the historical baseline of 21.9% observed in CCG-9941. The mean 1-year EFS (± standard deviation) was 14% ± 4.5%, compared with 21.9% ± 5% for CCG-9941. The P value of the test of comparison of 1-year EFS, based on a 1-sided, 1-sample test of proportions, was .96. There was no evidence that temozolomide produced a 1-year EFS rate higher than 21.9%. The mean 1-year OS (± standard deviation) was 40% ± 6.5%, compared with 32% ± 6% for CCG-9941. The median time to death was 9.6 months. Chemoradiotherapy with TMZ followed by adjuvant TMZ is not more effective than previously reported regimens for the treatment of children with DIPG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Packer, R. J., Krailo, M., Mehta, M. P., Warren, K. E., Allen, J. C., Jakacki, R. I., Villablanca, J. G., Chiba, A., & Reaman, G. H. (2005) · Cancer · doi:10.1002/cncr.21301 · Cited by 65
RetractedRadiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Paugh, B. S., Qu, C., Jones, C., Liu, Z., Adamowicz-Brice, M., Zhang, J., Bax, D. A., Coyle, B., Barrow, J., Hargrave, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7252 · Cited by 654
Diffuse brainstem glioma in children: critical review of clinical trials
Hargrave, D., Bartels, U., & Bouffet, E. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70615-5 · Cited by 634
Self-citationZarghooni, M., Bartels, U., Lee, E., Buczkowicz, P., Morrison, A., Huang, A., Bouffet, E., & Hawkins, C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5463 · Cited by 313
Self-citationProspective study of awake craniotomy used routinely and nonselectively for supratentorial tumors
Serletis, D., & Bernstein, M. (2007) · Journal of Neurosurgery · doi:10.3171/jns-07/07/0001 · Cited by 312
Quinn, J. A., Desjardins, A., Weingart, J., Brem, H., Dolan, M. E., Delaney, S. M., Vredenburgh, J., Rich, J., Friedman, A. H., Reardon, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.502 · Cited by 288
Advances Toward an Understanding of Brainstem Gliomas
Donaldson, S. S., Laningham, F., & Fisher, P. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6599 · Cited by 237
Pollack, I. F., Jakacki, R. I., Blaney, S. M., Hancock, M. L., Kieran, M. W., Phillips, P., Kun, L. E., Friedman, H., Packer, R., Banerjee, A., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2006-031 · Cited by 192
Self-citationKorones, D. N., Fisher, P. G., Kretschmar, C. S., Zhou, T., Chen, Z., Kepner, J. L., & Freeman, C. R. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21154 · Cited by 110
Self-citation
Cited by
Gholamin, S., Mitra, S. S., Feroze, A. H., Liu, J., Kahn, S. A., Zhang, M., Esparza, R., Richard, C., Ramaswamy, V., Remke, M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2968 · Cited by 426
Pediatric high-grade glioma: biologically and clinically in need of new thinking
Jones, C., Karajannis, M. A., Jones, D. T. W., Kieran, M. W., Monje, M., Baker, S. J., Becher, O. J., Cho, Y.-J., Gupta, N., Hawkins, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now101 · Cited by 360
Pollack, I. F., Agnihotri, S., & Broniscer, A. (2019) · Journal of Neurosurgery: Pediatrics · doi:10.3171/2018.10.peds18377 · Cited by 314
Self-citationDiffuse intrinsic pontine glioma: poised for progress
Warren, K. E. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00205 · Cited by 297
Characteristics of H3 K27M-mutant gliomas in adults
Meyronet, D., Esteban-Mader, M., Bonnet, C., Joly, M.-O., Uro-Coste, E., Amiel-Benouaich, A., Forest, F., Rousselot-Denis, C., Burel-Vandenbos, F., Bourg, V., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now274 · Cited by 279
Metadata
- Authors
- Cohen, K. J., Heideman, R. L., Zhou, T., Holmes, E. J., Lavey, R. S., Bouffet, E., & Pollack, I. F.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02-22
- Volume
- 13
- Issue
- 4
- Pages
- 410-416
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2106343920
- Cited by
- 331
- References
- 14
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. https://app.cochat.ai/papers/10.1093/neuonc/noq205
- The paper
- Cohen, K. J., Heideman, R. L., Zhou, T., Holmes, E. J., Lavey, R. S., Bouffet, E., & Pollack, I. F. (2011). Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro-Oncology. https://doi.org/10.1093/neuonc/noq205
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.